Johnson & Johnson CARVYKTI five-year data: 50% progression-free, 69.2% OS in early-line myeloma

J&J reports 50% of patients progression-free at five years without maintenance after single CARVYKTI infusion in early-line multiple myeloma. Five-year OS 69.2%, median PFS 60.5 months. Data from CARTITUDE-2 Cohort A (N=20) presented at IMS. No new neurotoxicity. Supports earlier use of CAR-T.